HSPA5 and neoplasm: Indeed, treatment with ML-SA1, a TRPML1 agonist (Figure 3A), induced a rapid intracellular Ca2+ increase, preventing the upregulation of GRP78 [134], which is associated with tumor cells proliferation and drug-resistance promotion [135].